ArticleESMO open2020
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
Aparna Hegde et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
33 papers cite it
this paperpooled ittrialcites it